Balversa
Payments companies reported to CMS as associated with Balversa. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Balversa, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Balversa
These are the largest totals companies reported as associated with Balversa. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Arlene Siefker-Radtke | Houston, TX | Medical Oncology | $1,603.38 |
| Scott Tagawa | New York, NY | Hematology & Oncology | $1,206.24 |
| Yung Lyou | Fullerton, CA | Hematology & Oncology | $1,090.00 |
| Patrick Pilie | Houston, TX | Internal Medicine | $616.90 |
| Arash Rezazadeh Kalebasty | Orange, CA | Hematology & Oncology | $597.61 |
| Sumit Subudhi | Houston, TX | Medical Oncology | $522.31 |
| Patrick Hensley | Lexington, KY | Urology | $448.87 |
| Kayla Desuza | Orlando, FL | Hematology (Internal Medicine) | $443.83 |
| Brian Chapin | Houston, TX | Urology | $440.10 |
| Matthew Campbell | Houston, TX | Internal Medicine | $388.57 |
Prescribed Balversa?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.